Detailed information for compound 251017

Basic information

Technical information
  • TDR Targets ID: 251017
  • Name: 11-Ethyl-2,4-dimethyl-5,11-dihydro-6H-dipyrid o[2,3-e:3',2'-b][1,4]diazepin-6-one
  • MW: 268.314 | Formula: C15H16N4O
  • H donors: 1 H acceptors: 3 LogP: 2.17 Rotable bonds: 1
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCn1c2nc(C)cc(c2[nH]c(=O)c2c1nccc2)C
  • InChi: 1S/C15H16N4O/c1-4-19-13-11(6-5-7-16-13)15(20)18-12-9(2)8-10(3)17-14(12)19/h5-8H,4H2,1-3H3,(H,18,20)
  • InChiKey: UDDMNBYVRLYNKY-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • AIDS-033563
  • AIDS033563
  • Dipyridodiazepinone deriv. 5

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Human immunodeficiency virus 1 Human immunodeficiency virus type 1 reverse transcriptase Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma mansoni hypothetical protein Get druggable targets OG5_139608 All targets in OG5_139608
Trypanosoma congolense RNA helicase, putative Get druggable targets OG5_139608 All targets in OG5_139608
Plasmodium yoelii integrase-related Get druggable targets OG5_139608 All targets in OG5_139608
Trypanosoma brucei RNA helicase, putative Get druggable targets OG5_139608 All targets in OG5_139608
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi FAD binding domain containing protein 0.0058 0.4137 1
Trypanosoma cruzi NADPH-dependent FMN/FAD containing oxidoreductase, putative 0.0058 0.4137 0.5
Echinococcus multilocularis NADPH dependent diflavin oxidoreductase 1 0.0058 0.4137 1
Toxoplasma gondii flavodoxin domain-containing protein 0.0029 0 0.5
Leishmania major p450 reductase, putative 0.0058 0.4137 1
Giardia lamblia Nitric oxide synthase, inducible 0.0052 0.3203 0.5
Giardia lamblia Hypothetical protein 0.0052 0.3203 0.5
Loa Loa (eye worm) FAD binding domain-containing protein 0.0058 0.4137 1
Trypanosoma cruzi cytochrome P450 reductase, putative 0.0058 0.4137 0.5
Mycobacterium ulcerans formate dehydrogenase H FdhF 0.0058 0.4137 0.5
Schistosoma mansoni cytochrome P450 reductase 0.0058 0.4137 0.4137
Toxoplasma gondii flavodoxin domain-containing protein 0.0029 0 0.5
Plasmodium vivax NADPH-cytochrome p450 reductase, putative 0.0058 0.4137 1
Trypanosoma cruzi cytochrome P450 reductase, putative 0.0058 0.4137 0.5
Chlamydia trachomatis sulfite reductase 0.0036 0.0996 0.5
Echinococcus granulosus NADPH cytochrome P450 reductase 0.0058 0.4137 1
Schistosoma mansoni NADPH flavin oxidoreductase 0.0029 0.0062 0.0062
Echinococcus multilocularis NADPH cytochrome P450 reductase 0.0058 0.4137 1
Leishmania major NADPH-cytochrome p450 reductase-like protein 0.0058 0.4137 1
Schistosoma mansoni 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase 0.0036 0.0996 0.0996
Loa Loa (eye worm) hypothetical protein 0.0058 0.4137 1
Trypanosoma brucei RNA helicase, putative 0.01 1 1
Brugia malayi flavodoxin family protein 0.0058 0.4137 1
Trypanosoma cruzi p450 reductase, putative 0.0058 0.4137 0.5
Echinococcus granulosus NADPH dependent diflavin oxidoreductase 1 0.0058 0.4137 1
Trichomonas vaginalis sulfite reductase, putative 0.0058 0.4137 1
Plasmodium falciparum nitric oxide synthase, putative 0.0058 0.4137 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.02 uM Inhibitory concentration against HIV-1 wild type Reverse transcriptase(RT) ChEMBL. 7490732
IC50 (binding) = 0.02 uM Inhibitory concentration against HIV-1 wild type Reverse transcriptase(RT) ChEMBL. 7490732
IC50 (binding) > 1 uM Inhibitory activity against HIV-1 Y181C Reverse transcriptase(RT) ChEMBL. 7490732
IC50 (binding) > 1 uM Inhibitory activity against HIV-1 Y181C Reverse transcriptase(RT) ChEMBL. 7490732

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.